Special Issue

Novel Aspects of Molecular Targets for Antidepressant Drugs

Message from the Guest Editor

Major depressive disorder (MDD) is the third leading cause of disability worldwide and can have a tremendous impact on quality of life. For half a century, clinical antidepressants have acted with therapeutic effect by regulating monoamine transmitters, inhibiting the reuptake of 5- HT and NE, and increasing the levels of 5- HT, NE, or DA in the presynaptic membrane. But problems still exist. Recently, rapid-acting antidepressants, represented by ketamine, have received much attention. The possible mechanism is related to blocking NMDA receptors and activating AMPA receptors. This research topic investigates glutamatergic receptors such as NMDA, APMA, and GluR and the related fast-acting antidepressant mechanisms. The contents mainly include the three aspects: (1) use of artificial intelligence and computational design approaches to discover powerful fast-acting compounds that bind to the glutamate receptor; (2) novel approaches, including CRISPR/cas9 and multi-omics methods, have been used to explore the biological mechanism; and (3) new multi-target antidepressants (including melatonin receptor agonists, GABA receptor modulators, etc.), medicinal plants and their extracts.

Guest Editor

Dr. Qingzhong Wang
Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China

Deadline for manuscript submissions

closed (30 September 2023)

Molecules

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed

mdpi.com/si/138465

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

mdpi.com/journal/molecules

Molecules

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed

mdpi.com/journal/molecules

About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to molecular chemistry, now in its 30th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts, and novel materials. Pushing the boundaries of the discipline, we invite papers on all major fields of molecular chemistry and multidisciplinary topics bridging chemistry with biology, physics, and materials science, as well as timely reviews and topical issues on cutting-edge fields in all of these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt
Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the second half of 2025).

MDPI